ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Japan’s Astellas Pharma and Switzerland’s Anokion are joining to create a new company, Kanyos Bio, based on technology from Anokion, a spin-off from Switzerland’s ETH Lausanne. Anokion has developed antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and treat autoimmune and allergic diseases. Kanyos will launch in Cambridge, Mass., with $16 million in financing and will target treatments for type 1 diabetes and celiac disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter